My mistake. The information from clinicaltrials.gov for MTC trial made me believe 125mg was used in MTC trial as in GBM ph2 trial (Safety and tolerability at 125 mg XL184: The lower dose of 125 mg XL184 appears to provide clinically meaningful improvement in safety and tolerability, while maintaining a high rate of durable response in this recurrent GB population from ASCO 2010):
1: Experimental Intervention: Drug: XL184
Drug: XL184 Gelatin capsules supplied in 25-mg and 100-mg strengths administered orally daily
2: Placebo Comparator Intervention: Drug: Placebo
Drug: Placebo Gelatin capsules color and size-matched to XL184 capsules administered orally daily
Market Data 
Markets 
AI
